Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Clareo Health | Pancreatic Cancer Clinical Trials in Dallas | 209 Studies

Clinical Trials Pancreatic CancerDallas

Pancreatic Cancer Clinical Trials in Dallas

Find 209 clinical trials for pancreatic cancer near Dallas, Texas. Connect with research centers in your area.

All Pancreatic Cancer trials nationwide All trials in Dallas

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 141-160 of 209 trials

CompletedA Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic CancerThe primary purpose of this study is to assess the safety and effectiveness of TNFerade™ Biologic when administered concurrently with 5-FU and radiation therapy as first-line…NCT00051467·La Jolla, California and 24 others

Pancreatic Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedPilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic CancerThe purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem manganese (GC4419) or…NCT03340974·Tampa, Florida and 5 others

CompletedA Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric AdenocarcinomaThis is a phase 1, open-label, dose-escalation clinical trial to evaluate the safety and tolerability of ASG-5ME and identify the maximum tolerated dose in patients with…NCT01166490·Scottsdale, Arizona and 6 others

TerminatedStudy of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid TumorsThis study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene…NCT04383210·Birmingham, Alabama and 41 others

CompletedRadio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry.Bile duct cancer and pancreatic cancer are cancers that cannot be surgically removed.NCT04937322·Dallas, Texas

RecruitingA Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsThis study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors.NCT05208762·Birmingham, Alabama and 61 others

CompletedPhase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid TumorsThe key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced…NCT03102320·Phoenix, Arizona and 71 others

Active not recruitingCisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine CarcinomasThis randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients…NCT02595424·Kingman, Arizona and 672 others

TerminatedNUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNUV-868-01 is a first-in human, open- label, Phase 1/2 dose escalation and expansion study in patients with advanced solid tumors.NCT05252390·Tucson, Arizona and 21 others

CompletedA Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid TumorsThis will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed…NCT04672460·Encinitas, California and 30 others

CompletedA Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal CancerThis is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).NCT03819387·Beverly Hills, California and 8 others

CompletedPEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic CancerThis study is designed to compare the treatment effect of PEGPH20 combined with nab-paclitaxel (NAB) and gemcitabine (GEM) \[PAG\] to NAB and GEM \[AG\] in participants with Stage…NCT01839487·Birmingham, Alabama and 50 others

UnknownPancreatic Cancer & Surgical ResectionPrimary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best…NCT05170802·Dallas, Texas

CompletedS1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by SurgeryThis randomized phase II trial studies how well fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) works and compares to gemcitabine hydrochloride…NCT02562716·Birmingham, Alabama and 806 others

RecruitingA Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsGenes contain genetic code which tell the body which proteins to make. Many types of cancer are caused by changes, or mutations, in a gene called KRAS.NCT07094204·Santa Monica, California and 19 others

CompletedA Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic CancerThis is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398…NCT02231723·Phoenix, Arizona and 11 others

Active not recruitingBasket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK…NCT02568267·Phoenix, Arizona and 119 others

CompletedTrial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsA Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or…NCT05997056·Newport Beach, California and 3 others

CompletedCPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersThis is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in…NCT03454451·Tucson, Arizona and 26 others

RecruitingKO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsThis first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in…NCT06026410·Phoenix, Arizona and 37 others

PreviousPage 8 of 11Next

Other Conditions in Dallas

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia